William Blair Investment Management LLC Buys 1,107,083 Shares of Amicus Therapeutics, Inc. $FOLD

William Blair Investment Management LLC increased its position in shares of Amicus Therapeutics, Inc. (NASDAQ:FOLD) by 7.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 15,749,240 shares of the biopharmaceutical company’s stock after buying an additional 1,107,083 shares during the quarter. William Blair Investment Management LLC owned 5.10% of Amicus Therapeutics worth $124,104,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in FOLD. Osaic Holdings Inc. lifted its position in shares of Amicus Therapeutics by 450.1% in the 2nd quarter. Osaic Holdings Inc. now owns 4,104 shares of the biopharmaceutical company’s stock worth $25,000 after acquiring an additional 3,358 shares during the period. EverSource Wealth Advisors LLC lifted its position in Amicus Therapeutics by 472.6% in the second quarter. EverSource Wealth Advisors LLC now owns 4,455 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 3,677 shares during the period. Strs Ohio acquired a new stake in Amicus Therapeutics during the first quarter worth $30,000. ANTIPODES PARTNERS Ltd bought a new stake in Amicus Therapeutics in the 3rd quarter valued at $31,000. Finally, Versant Capital Management Inc raised its stake in shares of Amicus Therapeutics by 499.1% in the 3rd quarter. Versant Capital Management Inc now owns 5,266 shares of the biopharmaceutical company’s stock valued at $41,000 after buying an additional 4,387 shares in the last quarter.

Analyst Ratings Changes

A number of research firms recently weighed in on FOLD. The Goldman Sachs Group upped their target price on shares of Amicus Therapeutics from $9.00 to $11.00 and gave the company a “neutral” rating in a research note on Wednesday, November 5th. Cantor Fitzgerald lowered Amicus Therapeutics from an “overweight” rating to a “hold” rating and lowered their price objective for the company from $21.00 to $14.50 in a research note on Friday, December 19th. Leerink Partners downgraded Amicus Therapeutics from an “outperform” rating to a “market perform” rating and cut their target price for the stock from $17.00 to $14.50 in a research report on Monday, December 29th. Needham & Company LLC cut Amicus Therapeutics from a “buy” rating to a “hold” rating in a research report on Friday, December 19th. Finally, Wall Street Zen raised shares of Amicus Therapeutics from a “buy” rating to a “strong-buy” rating in a report on Saturday, November 8th. Three research analysts have rated the stock with a Buy rating, nine have assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company currently has an average rating of “Hold” and an average target price of $15.39.

Insider Buying and Selling

In other Amicus Therapeutics news, insider David Michael Clark sold 25,643 shares of the stock in a transaction on Monday, December 15th. The stock was sold at an average price of $11.00, for a total value of $282,073.00. Following the transaction, the insider directly owned 271,332 shares in the company, valued at approximately $2,984,652. This trade represents a 8.63% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CEO Bradley L. Campbell sold 77,926 shares of the business’s stock in a transaction on Monday, December 15th. The stock was sold at an average price of $10.86, for a total value of $846,276.36. Following the sale, the chief executive officer owned 1,129,782 shares of the company’s stock, valued at approximately $12,269,432.52. The trade was a 6.45% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold 218,798 shares of company stock worth $2,710,962 over the last quarter. 2.20% of the stock is owned by company insiders.

Amicus Therapeutics Price Performance

Shares of FOLD stock opened at $14.37 on Friday. Amicus Therapeutics, Inc. has a 52 week low of $5.51 and a 52 week high of $14.38. The stock has a market capitalization of $4.51 billion, a PE ratio of -179.63 and a beta of 0.38. The company has a debt-to-equity ratio of 1.43, a quick ratio of 2.09 and a current ratio of 2.84. The stock’s fifty day moving average is $14.29 and its 200-day moving average is $10.68.

Amicus Therapeutics (NASDAQ:FOLD) last released its quarterly earnings results on Friday, February 20th. The biopharmaceutical company reported $0.10 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.13 by ($0.03). Amicus Therapeutics had a negative net margin of 4.27% and a positive return on equity of 4.15%. The business had revenue of $185.21 million during the quarter, compared to the consensus estimate of $185.00 million. During the same period in the prior year, the firm earned $0.09 earnings per share. The business’s quarterly revenue was up 23.7% compared to the same quarter last year. Equities research analysts expect that Amicus Therapeutics, Inc. will post 0.15 EPS for the current fiscal year.

Amicus Therapeutics Company Profile

Amicus Therapeutics (NASDAQ:FOLD) is a biopharmaceutical company focused on the discovery, development and commercialization of treatments for rare and orphan diseases. The company specializes in pharmacological chaperones and gene therapy approaches designed to address the underlying causes of lysosomal storage disorders. Its proprietary technology platform integrates structure‐based drug design with precision medicine to identify small molecules that stabilize misfolded proteins and restore cellular function.

The company’s lead marketed product, Galafold (migalastat), is an oral pharmacological chaperone approved in the United States, European Union and other territories for the treatment of Fabry disease in patients with amenable genetic variants.